Successful Treatment of Legionnaires' Disease with Tigecycline in an Immunocompromised Man with a Legion of Antibiotic Allergies.

Autor:	Arget M; Internal Medicine, University of Saskatchewan College of Medicine, Saskatoon, CAN., Kosar J; Miscellaneous, Saskatchewan Health Authority, Saskatoon, CAN., Suen B; Internal Medicine, University of Saskatchewan College of Medicine, Saskatoon, CAN., Peermohamed S; Internal Medicine / Infectious Disease, University of Saskatchewan College of Medicine, Saskatoon, CAN.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2019 Apr 30; Vol. 11 (4), pp. e4577. Date of Electronic Publication: 2019 Apr 30.
DOI:	10.7759/cureus.4577
Abstrakt:	Legionella species are Gram-negative bacilli that are relatively rare causes of community-acquired pneumonia but can be associated with significant morbidity and mortality if unrecognized or improperly treated. Limited data exist regarding the use of tigecycline, a third generation glycylcycline, in the treatment of Legionnaires' disease. We present an immunocompromised patient with Legionnaires' disease and allergies to both fluoroquinolones and macrolides, which are first-line treatment options for Legionnaires' disease. He was successfully treated using tigecycline, a third generation glycylcycline, indicating that tigecycline may serve as a safe and effective alternative therapeuticl option for treatment of Legionnaires' disease. Competing Interests: The authors have declared that no competing interests exist.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu